Trial Profile
Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia (STIM).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Dasatinib; Nilotinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms STIM
- 20 Jan 2017 Results published in the Journal of Clinical Oncology
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.